MedPath

IceCure Medical CEO Highlights 2021 Achievements and 2022 Objectives

4 years ago2 min read

Regulatory and Clinical Progress

  • ICE3 Clinical Trial: Positive interim results were presented at major medical conferences, demonstrating the efficacy and safety of the ProSense® system for minimally invasive cryoablation of small breast cancer tumors.
  • Regulatory Achievements: Granted Breakthrough Device Designation by the FDA for the ProSense® system, submitted a pre-submission package to the FDA for early-stage breast cancer treatment, and submitted an amendment to China's NMPA for the IceSense3® system.

Commercial Expansion

  • Global Distribution: Expanded distribution networks in Turkey, India, Brazil, Thailand, Japan, Singapore, and Poland.
  • Financial Milestones: Completed a $15 million private placement and a $17 million follow-on offering, with shares commencing trading on the Nasdaq Capital Market.

Future Objectives

  • 2022 Focus: Aiming for regulatory clearance in the United States, China, and Japan, and continuing the development of next-generation single and multi-probe systems for treating larger or multiple tumors.
  • Strategic Partnerships: Cooperating with Terumo Corporation to advance the regulatory process in Japan.

Acknowledgments

  • Team and Shareholders: Expressed gratitude for the team's efforts and shareholders' support, emphasizing the company's commitment to advancing cryoablation technology for tumor therapy.
IceCure Medical continues to focus on becoming the new gold-standard for cryoablation tumor therapy, leveraging its minimally-invasive technology to offer safe and effective alternatives to surgical tumor removal.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.